Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial - 29/09/20
, Alessandro Gronchi, MD b, Cécile Le Péchoux, MD d, Carol J Swallow, ProfMD f, Dirk Strauss, MD h, Pierre Meeus, MD j, Frits van Coevorden, MD l, Stephan Stoldt, MD n, Eberhard Stoeckle, MD o, Piotr Rutkowski, ProfPhD p, Marco Rastrelli, MD q, Chandrajit P Raut, ProfMD r, t, u, Daphne Hompes, ProfMD v, Antonino De Paoli, MD w, Claudia Sangalli, MD c, Charles Honoré, PhD e, Peter Chung, MD g, Aisha Miah, MD i, Jean Yves Blay, ProfPhD k, Marco Fiore, MD b, Jean-Jacques Stelmes, MD x, Angelo P Dei Tos, ProfMD aa, Elizabeth H Baldini, ProfMD s, t, u, Saskia Litière, PhD y, Sandrine Marreaud, MD z, Hans Gelderblom, ProfPhD ab, Rick L Haas, ProfPhD mSummary |
Background |
Unlike for extremity sarcomas, the efficacy of radiotherapy for retroperitoneal sarcoma is not established. The aim of this study was to evaluate the impact of preoperative radiotherapy plus surgery versus surgery alone on abdominal recurrence-free survival.
Methods |
EORTC-62092 is an open-label, randomised, phase 3 study done in 31 research institutions, hospitals, and cancer centres in 13 countries in Europe and North America. Adults (aged ≥18 years) with histologically documented, localised, primary retroperitoneal sarcoma that was operable and suitable for radiotherapy, who had not been previously treated and had a WHO performance status and American Society of Anesthesiologists score of 2 or lower, were centrally randomly assigned (1:1), using an interactive web response system and a minimisation algorithm, to receive either surgery alone or preoperative radiotherapy followed by surgery. Randomisation was stratified by hospital and performance status. Radiotherapy was delivered as 50·4 Gy (in 28 daily fractions of 1·8 Gy) in either 3D conformal radiotherapy or intensity modulated radiotherapy, and the objective of surgery was a macroscopically complete resection of the tumour mass with en-bloc organ resection as necessary. The primary endpoint was abdominal recurrence-free survival, as assessed by the investigator, and was analysed in the intention-to-treat population. Safety was analysed in all patients who started their allocated treatment. This trial is registered with ClinicalTrials.gov, NCT01344018.
Findings |
Between Jan 18, 2012 and April 10, 2017, 266 patients were enrolled, of whom 133 were randomly assigned to each group. The median follow-up was 43·1 months (IQR 28·8–59·2). 128 (96%) patients from the surgery alone group had surgery, and 119 (89%) patients in the radiotherapy and surgery group had both radiotherapy and surgery. Median abdominal recurrence-free survival was 4·5 years (95% CI 3·9 to not estimable) in the radiotherapy plus surgery group and 5·0 years (3·4 to not estimable) in the surgery only group (hazard ratio 1·01, 95% CI 0·71–1·44; log rank p=0·95). The most common grade 3–4 adverse events were lymphopenia (98 [77%] of 127 patients in the radiotherapy plus surgery group vs one [1%] of 128 patients in the surgery alone group), anaemia (15 [12%] vs ten [8%]), and hypoalbuminaemia (15 [12%] vs five [4%]). Serious adverse events were reported in 30 (24%) of 127 patients in the radiotherapy plus surgery group, and in 13 (10%) of 128 patients in the surgery alone group. One (1%) of 127 patients in the radiotherapy plus surgery group died due to treatment-related serious adverse events (gastropleural fistula), and no patients in the surgery alone group died due to treatment-related serious adverse events.
Interpretation |
Preoperative radiotherapy should not be considered as standard of care treatment for retroperitoneal sarcoma.
Funding |
European Organisation for Research and Treatment of Cancer, and European Clinical Trials in Rare Sarcomas.
Le texte complet de cet article est disponible en PDF.Plan
Vol 21 - N° 10
P. 1366-1377 - octobre 2020 Retour au numéro
Article précédent
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
- Aurélien Marabelle, Marwan Fakih, Juanita Lopez, Manisha Shah, Ronnie Shapira-Frommer, Kazuhiko Nakagawa, Hyun Cheol Chung, Hedy L Kindler, Jose A Lopez-Martin, Wilson H Miller, Antoine Italiano, Steven Kao, Sarina A Piha-Paul, Jean-Pierre Delord, Robert R McWilliams, David A Fabrizio, Deepti Aurora-Garg, Lei Xu, Fan Jin, Kevin Norwood, Yung-Jue Bang
- Genetic risk, incident gastric cancer, and healthy lifestyle: a meta-analysis of genome-wide association studies and prospective cohort study
- Guangfu Jin, Jun Lv, Ming Yang, Mengyun Wang, Meng Zhu, Tianpei Wang, Caiwang Yan, Canqing Yu, Yanbing Ding, Gang Li, Chuanli Ren, Jing Ni, Ruoxin Zhang, Yu Guo, Zheng Bian, Yan Zheng, Nasha Zhang, Yue Jiang, Jiaping Chen, Yanong Wang, Dazhi Xu, Hong Zheng, Ling Yang, Yiping Chen, Robin Walters, Iona Y Millwood, Juncheng Dai, Hongxia Ma, Kexin Chen, Zhengming Chen, Zhibin Hu, Qingyi Wei, Hongbing Shen, Liming Li
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?